

# Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2019

<https://marketpublishers.com/r/C45CC36CA52EN.html>

Date: December 2019

Pages: 81

Price: US\$ 3,500.00 (Single User License)

ID: C45CC36CA52EN

## Abstracts

Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2019

### SUMMARY

According to the recently published report 'Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2019'; Calcitonin Gene Related Peptide (CGRP) pipeline Target constitutes close to 9 molecules.

Calcitonin Gene Related Peptide (CGRP) - Calcitonin gene related peptide (CGRP) is a member of the calcitonin family of peptides. It exists in two forms alpha-CGRP and beta-CGRP. CGRP is produced in both peripheral and central neurons. CGRP is derived mainly from the cell bodies of motor neurons when synthesized in the ventral horn of the spinal cord and contribute to the regeneration of nervous tissue after injury. CGRP is derived from dorsal root ganglion when synthesized in the dorsal horn of the spinal cord and linked to the transmission of pain. CGRP also plays an important role in cardiovascular homeostasis and nociception.

The report 'Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2019' outlays comprehensive information on the Calcitonin Gene Related Peptide (CGRP) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase

III, Preclinical and Discovery stages are 2, 1, 4 and 2 respectively. Report covers products from therapy areas Central Nervous System and Immunology which include indications Migraine, Cluster Headache Syndrome (Cluster Headache), Dental Pain (Toothache/Tooth Pain), Fibromyalgia (Fibromyalgia Syndrome), Inflammatory Pain, Osteoarthritis Pain, Pain, Psoriasis and Traumatic Pain.

## **SCOPE**

The report provides a snapshot of the global therapeutic landscape for Calcitonin Gene Related Peptide (CGRP)

The report reviews Calcitonin Gene Related Peptide (CGRP) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Calcitonin Gene Related Peptide (CGRP) targeted therapeutics and enlists all their major and minor projects

The report assesses Calcitonin Gene Related Peptide (CGRP) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Calcitonin Gene Related Peptide (CGRP) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to

formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Calcitonin Gene Related Peptide (CGRP)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Calcitonin Gene Related Peptide (CGRP) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Calcitonin Gene Related Peptide (CGRP) - Overview

Calcitonin Gene Related Peptide (CGRP) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Calcitonin Gene Related Peptide (CGRP) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Calcitonin Gene Related Peptide (CGRP) - Companies Involved in Therapeutics Development

AfaSci Inc

Aptarion biotech AG

Eli Lilly and Co

H. Lundbeck AS

Living Cell Technologies Ltd

Nepsone ehf

Pharmnovo AB

Serometrix LLC

Teva Pharmaceutical Industries Ltd

Calcitonin Gene Related Peptide (CGRP) - Drug Profiles

AFAP-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eptinezumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fremanezumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

galcanezumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LP-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NOXL-41 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CGRP for Migraine and Osteoarthritis Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CGRP for Pain - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit CGRP for Psoriasis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Calcitonin Gene Related Peptide (CGRP) - Dormant Products

Calcitonin Gene Related Peptide (CGRP) - Discontinued Products

Calcitonin Gene Related Peptide (CGRP) - Product Development Milestones

Featured News & Press Releases

Oct 24, 2019: Teva to present new analyses of fremanezumab and country-specific burden of migraine at 24th World Congress of Neurology

Oct 02, 2019: EMGALITY (galcanezumab) now available in Canada for preventive treatment of migraine

Sep 05, 2019: Alder BioPharmaceuticals to Showcase Eptinezumab Data from Migraine Prevention Portfolio at 19th Congress of the International Headache Society

Sep 05, 2019: Lilly's migraine treatment Emgality lands in Korea

Sep 03, 2019: Teva to Present New Analyses of Fremanezumab Efficacy and Safety in Adult Patients with Difficult-to-Treat Migraine at 19th Congress of the International Headache Society

Aug 21, 2019: Fremanezumab data in The Lancet demonstrate clinically meaningful reduction in monthly migraine days versus Placebo for patients with difficult-to-treat

## migraine

Aug 06, 2019: Lilly reports positive data from CONQUER study of Emgality

Jul 15, 2019: Lilly's Emgality shows favourable profile in Phase III studies

Jul 11, 2019: New England Journal of Medicine publishes positive phase 3 data for Emgality (galcanezumab-gnlm) in episodic cluster headache

Jul 11, 2019: Alder BioPharmaceuticals presents new data on migraine-free months, migraine severity and quality of life, demonstrating eptinezumab's clinical profile for migraine prevention

Jul 10, 2019: Teva to present new data on AJOVY (fremanezumab-vfrm) injection at the American Headache Society's 61st Annual Scientific Meeting

Jul 09, 2019: Teva's Fremanezumab improves migraine-related disorders, quality of life

Jul 08, 2019: Alder BioPharmaceuticals to showcase 14 new data presentations demonstrating Eptinezumab's migraine prevention and quality of life impact at American Headache Society Meeting

Jul 04, 2019: Teva reports positive data from fremanezumab's migraine trial

Jun 19, 2019: Alder BioPharmaceuticals to webcast upcoming breakfast symposium with key opinion leaders

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by AfaSci Inc, H2 2019

Pipeline by Aptarion biotech AG, H2 2019

Pipeline by Eli Lilly and Co, H2 2019

Pipeline by H. Lundbeck AS, H2 2019

Pipeline by Living Cell Technologies Ltd, H2 2019

Pipeline by Nepsone ehf, H2 2019

Pipeline by Pharmnovo AB, H2 2019

Pipeline by Serometrix LLC, H2 2019

Pipeline by Teva Pharmaceutical Industries Ltd, H2 2019

Dormant Projects, H2 2019

Discontinued Products, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

AfaSci Inc

Aptarion biotech AG

Eli Lilly and Co

H. Lundbeck AS

Living Cell Technologies Ltd

Nepsone ehf

Pharmnovo AB

Serometrix LLC

Teva Pharmaceutical Industries Ltd



## I would like to order

Product name: Calcitonin Gene Related Peptide (CGRP) - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/C45CC36CA52EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C45CC36CA52EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970